Cargando…
Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test
(1) Objective: To investigate the factors that affect rates of neutralizing antibody production and duration after vaccination using the newly developed SARS-CoV-2 POCT. (2) Methods: The production of immunoglobulin and neutralizing antibody in clinical subjects who completed various vaccines was an...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406444/ https://www.ncbi.nlm.nih.gov/pubmed/36010274 http://dx.doi.org/10.3390/diagnostics12081924 |
_version_ | 1784774122444685312 |
---|---|
author | Shim, Hyeon Woo Shin, Jae hang Shin, Shang Cheol Lee, Hwa Jung So, Kyung Soon Lee, So Young Jun, Jae Woo Seo, Jeong Ku Lee, Hwa Seop Lee, Suk Young Kim, Seung Hyun Kim, Sun Jong Kim, Kyoung-Chol Ryu, Gyu Ha |
author_facet | Shim, Hyeon Woo Shin, Jae hang Shin, Shang Cheol Lee, Hwa Jung So, Kyung Soon Lee, So Young Jun, Jae Woo Seo, Jeong Ku Lee, Hwa Seop Lee, Suk Young Kim, Seung Hyun Kim, Sun Jong Kim, Kyoung-Chol Ryu, Gyu Ha |
author_sort | Shim, Hyeon Woo |
collection | PubMed |
description | (1) Objective: To investigate the factors that affect rates of neutralizing antibody production and duration after vaccination using the newly developed SARS-CoV-2 POCT. (2) Methods: The production of immunoglobulin and neutralizing antibody in clinical subjects who completed various vaccines was analyzed using the POCT, the semi-quantitative was interpreted by measurement application, and the quantified neutralizing antibody titers were using the ELISA. (3) Results: According to the clinical performance analysis of the POCT, the clinical sensitivity and the specificity were 96.8% (90/93) and 97.7% (167/171), respectively, for the S1 RBD IgG antibody. The clinical sensitivity was 92.22% (83/90), and the clinical specificity was 100.00% (174/174) for neutralizing antibodies. Factors influencing antibody production were analyzed using the whole blood of the five types of second-completed vaccinators (N = 736, 20–80 years old). General and neutralizing antibody and showed significant differences in age (p < 0.0001), vaccine type (p < 0.0001), inoculation interval (p < 0.0001), pain score (p < 0.0001), diabetes (p < 0.0001), and hypertension (p = 0.002). The gender (p = 0.021) and chronic fatigue (p = 0.02) did not show the significance. (4) Conclusions: An acquisition of immunoglobulin and neutralizing antibody varies according to vaccine type, age, days after vaccination, pain degree after vaccination, and underlying diseases. The POCT used in this study will be utilized for clinical recommendations such as deciding whether to receive additional vaccines through the immediate rapid determination of neutralizing antibody generation in the clinical site. |
format | Online Article Text |
id | pubmed-9406444 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94064442022-08-26 Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test Shim, Hyeon Woo Shin, Jae hang Shin, Shang Cheol Lee, Hwa Jung So, Kyung Soon Lee, So Young Jun, Jae Woo Seo, Jeong Ku Lee, Hwa Seop Lee, Suk Young Kim, Seung Hyun Kim, Sun Jong Kim, Kyoung-Chol Ryu, Gyu Ha Diagnostics (Basel) Article (1) Objective: To investigate the factors that affect rates of neutralizing antibody production and duration after vaccination using the newly developed SARS-CoV-2 POCT. (2) Methods: The production of immunoglobulin and neutralizing antibody in clinical subjects who completed various vaccines was analyzed using the POCT, the semi-quantitative was interpreted by measurement application, and the quantified neutralizing antibody titers were using the ELISA. (3) Results: According to the clinical performance analysis of the POCT, the clinical sensitivity and the specificity were 96.8% (90/93) and 97.7% (167/171), respectively, for the S1 RBD IgG antibody. The clinical sensitivity was 92.22% (83/90), and the clinical specificity was 100.00% (174/174) for neutralizing antibodies. Factors influencing antibody production were analyzed using the whole blood of the five types of second-completed vaccinators (N = 736, 20–80 years old). General and neutralizing antibody and showed significant differences in age (p < 0.0001), vaccine type (p < 0.0001), inoculation interval (p < 0.0001), pain score (p < 0.0001), diabetes (p < 0.0001), and hypertension (p = 0.002). The gender (p = 0.021) and chronic fatigue (p = 0.02) did not show the significance. (4) Conclusions: An acquisition of immunoglobulin and neutralizing antibody varies according to vaccine type, age, days after vaccination, pain degree after vaccination, and underlying diseases. The POCT used in this study will be utilized for clinical recommendations such as deciding whether to receive additional vaccines through the immediate rapid determination of neutralizing antibody generation in the clinical site. MDPI 2022-08-09 /pmc/articles/PMC9406444/ /pubmed/36010274 http://dx.doi.org/10.3390/diagnostics12081924 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Shim, Hyeon Woo Shin, Jae hang Shin, Shang Cheol Lee, Hwa Jung So, Kyung Soon Lee, So Young Jun, Jae Woo Seo, Jeong Ku Lee, Hwa Seop Lee, Suk Young Kim, Seung Hyun Kim, Sun Jong Kim, Kyoung-Chol Ryu, Gyu Ha Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test |
title | Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test |
title_full | Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test |
title_fullStr | Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test |
title_full_unstemmed | Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test |
title_short | Analysis of Factors Affecting Neutralizing Antibody Production after COVID-19 Vaccination Using Newly Developed Rapid Point-of-Care Test |
title_sort | analysis of factors affecting neutralizing antibody production after covid-19 vaccination using newly developed rapid point-of-care test |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406444/ https://www.ncbi.nlm.nih.gov/pubmed/36010274 http://dx.doi.org/10.3390/diagnostics12081924 |
work_keys_str_mv | AT shimhyeonwoo analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT shinjaehang analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT shinshangcheol analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT leehwajung analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT sokyungsoon analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT leesoyoung analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT junjaewoo analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT seojeongku analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT leehwaseop analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT leesukyoung analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT kimseunghyun analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT kimsunjong analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT kimkyoungchol analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest AT ryugyuha analysisoffactorsaffectingneutralizingantibodyproductionaftercovid19vaccinationusingnewlydevelopedrapidpointofcaretest |